Assetmark Inc. Acquires 4,621 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Assetmark Inc. raised its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 1,391.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,953 shares of the biotechnology company's stock after purchasing an additional 4,621 shares during the quarter. Assetmark Inc.'s holdings in BioMarin Pharmaceutical were worth $326,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. TD Private Client Wealth LLC increased its position in BioMarin Pharmaceutical by 57.4% in the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 186 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at $36,000. Meeder Asset Management Inc. raised its stake in shares of BioMarin Pharmaceutical by 920.8% during the third quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 663 shares in the last quarter. True Wealth Design LLC lifted its holdings in BioMarin Pharmaceutical by 13,400.0% in the third quarter. True Wealth Design LLC now owns 810 shares of the biotechnology company's stock worth $57,000 after purchasing an additional 804 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in BioMarin Pharmaceutical by 111.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 885 shares of the biotechnology company's stock valued at $58,000 after buying an additional 466 shares in the last quarter. Institutional investors own 98.71% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of analysts have recently weighed in on BMRN shares. Wedbush reaffirmed an "outperform" rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $70.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Piper Sandler lifted their price objective on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a research note on Thursday, February 20th. Finally, Bank of America increased their target price on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $94.00.

Insider Activity at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,344 shares of BioMarin Pharmaceutical stock in a transaction on Monday, February 24th. The shares were sold at an average price of $68.38, for a total transaction of $91,902.72. Following the completion of the transaction, the chief accounting officer now directly owns 13,105 shares of the company's stock, valued at $896,119.90. The trade was a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.85% of the stock is owned by company insiders.

BioMarin Pharmaceutical Trading Up 0.1 %

Shares of NASDAQ BMRN traded up $0.06 during midday trading on Thursday, reaching $70.60. 968,363 shares of the stock were exchanged, compared to its average volume of 1,775,537. BioMarin Pharmaceutical Inc. has a 12 month low of $60.63 and a 12 month high of $94.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. The company has a market capitalization of $13.47 billion, a price-to-earnings ratio of 32.09, a P/E/G ratio of 0.61 and a beta of 0.33. The business has a 50-day simple moving average of $66.08 and a two-hundred day simple moving average of $69.09.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million during the quarter, compared to analyst estimates of $711.05 million. As a group, equities research analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.